Study of durvalumab/placebo + chemoradiation therapy in Patients with Unresectable, Locally Advanced Non-small Cell Lung Cancer

Prior treatment

• '- Receipt of prior or current cancer treatment, including but not limited to, radiation therapy, investigational agents, chemotherapy, Durvalumab and mAbs. - Prior exposure to immune-mediated therapy, including but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines. - History of allogeneic organ transplantation - Active or prior documented autoimmune or inflammatory disorders - Uncontrolled intercurrent illness - History of another primary malignancy / leptomeningeal carcinomatosis / active primary immunodeficiency - Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus - Mixed small cell and NSCLC histology. - Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labelling - Known allergy or hypersensitivity to any of the IPs or any of the IP excipients. - Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving ≥20 Gy in total (V20) of more than 35% of lung volume. - Patients who have disease considered for surgical treatment as part of their care plan, such as Pancoast or superior sulcus tumors. Patients with T4 lesions that invade major vascular structures such as pulmonary artery or cardiac tissues are also not eligible.

• '- Subjects with histologically- or cytologically-documented NSCLC - Locally advanced or unresectable (Stage III) NSCLC - World Health Organization (WHO)/ Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrollment and randomization. - At least one measurable lesion, not previously irradiated - Must have a life expectancy of at least 12 weeks at randomization